The November 2016 announcement that Eli Lilly's investigational drug solanezumab failed in a phase 3 clinical trial dashed hopes that it would be a long-anticipated disease-modifying treatment for Alzheimer's disease. For people living with Alzheimer's — along with their relatives and caregivers,…
http://ift.tt/2pAGX3l
Αρχειοθήκη ιστολογίου
-
▼
2023
(138)
-
▼
Φεβρουαρίου
(74)
-
▼
Φεβ 19
(9)
- Multifunctional Two-Dimensional Bi2Se3 Nanodiscs f...
- Downregulation of miR‐193a/b‐3p during HPV‐induced...
- The ability of magnetic resonance imaging to predi...
- Frequent EGFR exon 20 insertion in the so‐called p...
- Central odontogenic fibroma with amyloid: a diagno...
- Tixagevimab/Cilgavimab Treatment and Cardiovascula...
- The Ixodes ricinus salivary gland proteome during ...
- Characterization of protein-based risk signature t...
- Acute Posterior Multifocal Placoid Pigment Epithel...
-
▼
Φεβ 19
(9)
- ► Ιανουαρίου (64)
-
▼
Φεβρουαρίου
(74)
-
►
2022
(849)
- ► Δεκεμβρίου (61)
- ► Σεπτεμβρίου (74)
- ► Φεβρουαρίου (65)
-
►
2021
(2936)
- ► Δεκεμβρίου (59)
- ► Σεπτεμβρίου (180)
- ► Φεβρουαρίου (325)
-
►
2020
(1624)
- ► Δεκεμβρίου (293)
- ► Σεπτεμβρίου (234)
- ► Φεβρουαρίου (28)
-
►
2019
(13362)
- ► Δεκεμβρίου (19)
- ► Σεπτεμβρίου (54)
- ► Φεβρουαρίου (5586)
- ► Ιανουαρίου (5696)
-
►
2018
(66471)
- ► Δεκεμβρίου (5242)
- ► Σεπτεμβρίου (5478)
- ► Φεβρουαρίου (4835)
- ► Ιανουαρίου (5592)
-
►
2017
(44259)
- ► Δεκεμβρίου (5110)
- ► Σεπτεμβρίου (5105)
-
►
2016
(7467)
- ► Δεκεμβρίου (514)
- ► Σεπτεμβρίου (1038)
- ► Φεβρουαρίου (793)
Αναζήτηση αυτού του ιστολογίου
Πέμπτη 4 Μαΐου 2017
The Failure of Solanezumab — How the FDA Saved Taxpayers Billions
Health Insurance and Emergency Department Use — A Complex Relationship
http://ift.tt/2p8vFjt
Resident Duty Hours and Medical Education Policy — Raising the Evidence Bar
On March 10, 2017, the Accreditation Council for Graduate Medical Education (ACGME) issued revised common program requirements for residents that go into effect this July. The revisions emphasize the importance of teamwork, flexibility, and physician welfare during training, but all the attention…
http://ift.tt/2pAykpC
The Failure of Solanezumab — How the FDA Saved Taxpayers Billions
http://ift.tt/2pAGX3l
Academic, Foundation, and Industry Collaboration in Finding New Therapies
Breakthroughs in the ability to probe and better understand biologic systems during the past 30 years have enabled the medical community to develop new therapeutic agents and change the course of many life-shortening diseases. Despite this success, bridging the gap between promising laboratory…
http://ift.tt/2p8umku
Systematic review: interventions for abdominal pain management in inflammatory bowel disease
Summary
Background
Abdominal pain is frequently reported by people with inflammatory bowel disease (IBD), including in remission. Pain is an under-treated symptom.
Aim
To systematically review evidence on interventions (excluding disease-modifying interventions) for abdominal pain management in IBD.
Methods
Databases (MEDLINE, EMBASE, PsycInfo, CINAHL, Scopus, Cochrane Library) were searched (February 2016). Two researchers independently screened references and extracted data.
Results
Fifteen papers were included: 13 intervention studies and two cross-sectional surveys. A variety of psychological, dietary and pharmacological interventions were reported. Four of six studies reported pain reduction with psychological intervention including individualised and group-based relaxation, disease anxiety-related Cognitive Behavioural Therapy and stress management. Both psychologist-led and self-directed stress management in inactive Crohn's disease reduced pain compared with controls (symptom frequency reduction index=−26.7, −11.3 and 17.2 at 6-month follow-up, respectively). Two dietary interventions (alcoholic drinks with high sugar content and fermentable carbohydrate with prebiotic properties) had an effect on abdominal pain. Antibiotics (for patients with bacterial overgrowth) and transdermal nicotine patches reduced abdominal pain. Current and past cannabis users report it relieves pain. One controlled trial of cannabis reduced SF-36 and EQ-5D pain scores (1.84 and 0.7, respectively). These results must be treated with caution: data were derived from predominantly small uncontrolled studies of moderate to low quality.
Conclusions
Few interventions have been tested for IBD abdominal pain. The limited evidence suggests that relaxation and changing cognitions are promising, possibly with individualised dietary changes. There is a need to develop interventions for abdominal pain management in IBD.
http://ift.tt/2pIwtgH
-
Pharmaceutics Pharmaceutics, Vol. 12, Pages 832: Optimized Birch Bark Extract-Loaded Colloidal Dispersion Using Hydrogenated Phospholipid...
-
Vaccines Vaccines, Vol. 8, Pages 492: Anti-Flavivirus Vaccines: Review of the Present Situation and Perspectives of Subunit Vaccines Prod...
-
Cells Cells, Vol. 9, Pages 2002: Low ARID1A Expression is Associated with Poor Prognosis in Hepatocellular Carcinoma Cells, Vol. 9, Pages...